Upload
Featured Recent Articles Topics Login Upload

Search Results for ''

published presentations and documents on DocSlides.

FDA’s New Final Guidance on
FDA’s New Final Guidance on
by pasty-toler
Drug Inspections. Anne K. Walsh. FDLI Enforcement...
Guidance for the ublic FDA Advisory Committee Members and FDA Staff The Open Public Hearing at FDA Advisory Committee Meetings FINAL GUIDANCE Comments and suggestions may be submitted at anytime for
Guidance for the ublic FDA Advisory Committee Members and FDA Staff The Open Public Hearing at FDA Advisory Committee Meetings FINAL GUIDANCE Comments and suggestions may be submitted at anytime for
by giovanna-bartolotta
1061 Rockville MD 20852 All comments should be id...
Guidance for Industry
Guidance for Industry
by davies
and FDA Staff Class II Special Controls Guidance D...
stributed for comment purposes onlyComments and suggestions regarding
stributed for comment purposes onlyComments and suggestions regarding
by natalia-silvester
G:\4156dft.doc 09/30/03 G:\4156dft.doc http...
Drug Products Labeled as HomeopathicGuidance for FDA Staffand Industry
Drug Products Labeled as HomeopathicGuidance for FDA Staffand Industry
by candy
. Submit written comments to the Dockets Managem...
FDA’s Center for Devices and Radiological Health: Current Status and Future Direction
FDA’s Center for Devices and Radiological Health: Current Status and Future Direction
by carny
Jeff Shuren, MD, JD. Center for Devices and Radiol...
FDA Antimicrobials Update
FDA Antimicrobials Update
by cheryl-pisano
James D. McKean, DVM, JD. Associate Director, Iow...
FDA Antimicrobials Update
FDA Antimicrobials Update
by celsa-spraggs
James D. McKean, DVM, JD. Associate Director, Iow...
1 FDA’s BIMO Inspection Program
1 FDA’s BIMO Inspection Program
by olivia-moreira
and. IRB Inspections. VA IRB Chairs Meeting. Aug...
Diane L. Heinz, DVM, MBA
Diane L. Heinz, DVM, MBA
by debby-jeon
Director. Policy and Regulations Staff. Center fo...
Diane L. Heinz, DVM, MBA
Diane L. Heinz, DVM, MBA
by test
Director. Policy and Regulations Staff. Center fo...
Guidance for the Public FDA Advisory Committee Members and FDA Staff Public Availability of Advisory Committee Members Financial Interest Information and Waivers FINAL GUIDANCE Comments and suggestio
Guidance for the Public FDA Advisory Committee Members and FDA Staff Public Availability of Advisory Committee Members Financial Interest Information and Waivers FINAL GUIDANCE Comments and suggestio
by ellena-manuel
1061 Rockville MD 20852 All comments should be id...
Gu idance for Industry IRB Rev ie w of StandA lone HIPAA Au thorizations Under FDA Regu lations FINAL GUIDANCE This guidance is being distributed for immediate implementation
Gu idance for Industry IRB Rev ie w of StandA lone HIPAA Au thorizations Under FDA Regu lations FINAL GUIDANCE This guidance is being distributed for immediate implementation
by briana-ranney
FDA is issuing this guidance for immediate implem...
Diane L. Heinz, DVM, MBA
Diane L. Heinz, DVM, MBA
by olivia-moreira
Director. Policy and Regulations Staff. Center fo...
Information Sheet Guidance for Institutional Review Boards Clinical I
Information Sheet Guidance for Institutional Review Boards Clinical I
by anastasia
http://www.fda.gov/ScienceResearch/SpecialTopics/R...
Guidance Document forDura Substitute Devices; Guidancefor IndustryDocu
Guidance Document forDura Substitute Devices; Guidancefor IndustryDocu
by kaptainpositive
PrefacePublic CommentComments and suggestions may ...
Guidance for Industry and FDA Staff Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA NDA or PMA DRAFT GUIDANCE This guidance document is being di stributed for
Guidance for Industry and FDA Staff Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA NDA or PMA DRAFT GUIDANCE This guidance document is being di stributed for
by test
Comments and suggestions regarding this draft doc...
Public Meeting: Pre-DSHEA Dietary Ingredients List
Public Meeting: Pre-DSHEA Dietary Ingredients List
by celsa-spraggs
FDA Office of Dietary Supplement Programs. Panel ...
THE NAME GAME Lisa M. Tittemore,
THE NAME GAME Lisa M. Tittemore,
by pasty-toler
Esq.. Sunstein Kann Murphy & Timbers LLP. Ju...
Patient Engagement in Drug Development
Patient Engagement in Drug Development
by debby-jeon
:. Experiences, Good Practices and Lessons Learne...
IN THIS SECTION Warning LettersCompliance Actions and Activities
IN THIS SECTION Warning LettersCompliance Actions and Activities
by sophia2
An official website of the United States governmen...
x0000x0000 xMCIxD 0 xMCIxD 0 Guidance for Industry2 xMCIxD
x0000x0000 xMCIxD 0 xMCIxD 0 Guidance for Industry2 xMCIxD
by smith
cdsnascderguid6019dftdoc 01/23/04 Draft 151 Not fo...
Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De
Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De
by anastasia
x0000x0000 x/Attxachexd /xBottxom x/BBoxx 3x014x33...
Importation of Certain FDAApproved Human Prescription Drugs Including
Importation of Certain FDAApproved Human Prescription Drugs Including
by elena
�� &#x/Att;¬he; [/; ott;&...
Guidance for Clinical Investigators Sponsors and Investigational New D
Guidance for Clinical Investigators Sponsors and Investigational New D
by jade
NOTE A stay is in effect for partsof subsection V...
Recent U.S. Regulatory Efforts on Complex Innovative Clinical Trial Design
Recent U.S. Regulatory Efforts on Complex Innovative Clinical Trial Design
by bery
John Scott, Ph.D.. Director, Division of Biostatis...
Digital health technology-derived clinical outcome assessments: considerations for regulatory decis
Digital health technology-derived clinical outcome assessments: considerations for regulatory decis
by jalin
Elektra Papadopoulos, MD, MPH. Acting Deputy Direc...
ClinicalDevelopmentofGeneTherapiesTheFirstThreeDecadesandCountingLari
ClinicalDevelopmentofGeneTherapiesTheFirstThreeDecadesandCountingLari
by jones
https://doi.org/10.1016/j.omtm.2020.10.004Correspo...
FDARegulationandApprovalofMedicalDevices19762020JonathanJDarrowSJD
FDARegulationandApprovalofMedicalDevices19762020JonathanJDarrowSJD
by barbara
OBJECTIVEToreviewthedevelopmentoflawsandstandardsa...
Scott Gottlieb MD
Scott Gottlieb MD
by eliza
1 October 10, 2018 Commissioner Food and Drug Admi...
Management Review Management
Management Review Management
by natalia-silvester
Representative: First Last. Date: . February . 4....
Guidance for Industry Regulation of Human Cells Tissues and Cellular and TissueBased Products HCTPs Small Entity Compliance Guide This guidance is for immediate implementation
Guidance for Industry Regulation of Human Cells Tissues and Cellular and TissueBased Products HCTPs Small Entity Compliance Guide This guidance is for immediate implementation
by lindy-dunigan
FDA is issuing this guidance for immediate implem...
Guidance for Industry and FDA Staff Commercially Distributed Analyte Specific Reagents ASRs Frequently Asked Questions Document issued on September The draft of this guidance docume nt was released
Guidance for Industry and FDA Staff Commercially Distributed Analyte Specific Reagents ASRs Frequently Asked Questions Document issued on September The draft of this guidance docume nt was released
by ellena-manuel
US Department of Health and Human Services Food a...
Guidance for Industry Adverse Reactions Section of Labeling for Huma
Guidance for Industry Adverse Reactions Section of Labeling for Huma
by alexa-scheidler
(Tel) 301-827-4573 (Internet) http://www.fda.gov/c...
Guidance for Industry and FDA Staff Dear Health Care Provider Le ters Improving Communication of Important Safety Information U
Guidance for Industry and FDA Staff Dear Health Care Provider Le ters Improving Communication of Important Safety Information U
by celsa-spraggs
S Department of Health and Human Services Food and...
Guidance for FDA Staff and Industry Marketed Unapprove
Guidance for FDA Staff and Industry Marketed Unapprove
by alexa-scheidler
440100 Marketed New Drugs Without Approved NDAs o...
Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants U
Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants U
by marina-yarberry
S Department of Health and Human Services Food and...
Guidance for Industry and FDA Staff Minimal Manipulation of Structural Tissue Jurisdictional Update For questions regarding this document contact Suzanne OShea Office of Combin ation Products at or
Guidance for Industry and FDA Staff Minimal Manipulation of Structural Tissue Jurisdictional Update For questions regarding this document contact Suzanne OShea Office of Combin ation Products at or
by alida-meadow
US Department of Health and Human Services Food a...
Guidance for Industry and FDA Staff Glass Syringes for Delivering Drug and Biological Products Technical Information to Supplement International Organization for Standardization ISO Standard DRAFT
Guidance for Industry and FDA Staff Glass Syringes for Delivering Drug and Biological Products Technical Information to Supplement International Organization for Standardization ISO Standard DRAFT
by tatiana-dople
Comments and suggestions regarding this draft doc...
Contains Nonbinding Recommendations Information Sheet Guidance For IRBs Clinical Investigators and Sponsors FDA Inspections of Clinical Investigators Additional copies are available from Office of Go
Contains Nonbinding Recommendations Information Sheet Guidance For IRBs Clinical Investigators and Sponsors FDA Inspections of Clinical Investigators Additional copies are available from Office of Go
by jane-oiler
fdagovScienceResearchSpecialTopicsRunningClinicalT...